Clinical trial fails for Progenics Pharmaceuticals
Biopharmaceutical company Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) reported this morning that its phase 3 clinical trials with Wyeth Pharmaceuticals (NYSE: WYE), for intravenous methylnaltrexone used in patients recovering from segmental colectomy surgical procedures failed. Shares plummeted 55.7%, or $7.55, to $6.00 in pre-market trading.
For detailed price information and recent news stories about Progenics Pharmaceuticals, click PGNX.
For access to the full article, you must be a registered member - it's FREE.
Already a member? Please log in below
Not Registered?
Register today and enjoy all that SmallCapInvestor.com has to offer, including:
- Daily small cap stock profiles.
- Intra-day coverage of Russell 2000 companies.
- Research and insights from our analysts.
- Special reports.
